BCLI
Brainstorm Cell Therapeutics Inc.
Biotechnology
Market Cap$7M
5Y Perf.-99.4%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
BCLI vs CLLS vs FATE vs AGEN vs NKTR
Revenue, margins, valuation, and 5-year total return — side by side.
CLLS
Cellectis S.A.
Biotechnology
Market Cap$280M
5Y Perf.-79.1%
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$280M
5Y Perf.-92.5%
AGEN
Agenus Inc.
Biotechnology
Market Cap$132M
5Y Perf.-95.0%
NKTR
Nektar Therapeutics
Biotechnology
Market Cap$1.69B
5Y Perf.-74.4%
BCLI vs CLLS vs FATE vs AGEN vs NKTR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BCLI | CLLS | FATE | AGEN | NKTR |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $7M | $280M | $280M | $132M | $1.69B |
| Revenue (TTM) | $849K | $75M | $7M | $114M | $55M |
| Net Income (TTM) | $-11M | $-35M | $-136M | $115K | $-164M |
| Gross Margin | 61.5% | 87.6% | — | 35.7% | 99.6% |
| Operating Margin | -14.0% | -35.1% | -22.2% | -17.7% | -237.9% |
| Forward P/E | 0.3x | — | — | 1.8x | — |
| Total Debt | $720K | $91M | $78M | $10M | $149M |
| Cash & Equiv. | $187K | $143M | $47M | $3M | $15M |
BCLI vs CLLS vs FATE vs AGEN vs NKTR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BCLI
CLLS
FATE
AGEN
NKTR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Brainstorm Cell The… (BCLI) | 100 | 0.6 | -99.4% |
| Cellectis S.A. (CLLS) | 100 | 20.9 | -79.1% |
| Fate Therapeutics, … (FATE) | 100 | 7.5 | -92.5% |
| Agenus Inc. (AGEN) | 100 | 5.0 | -95.0% |
| Nektar Therapeutics (NKTR) | 100 | 25.6 | -74.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BCLI vs CLLS vs FATE vs AGEN vs NKTR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BCLI and AGEN are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Agenus Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. CLLS and NKTR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
BCLI
Brainstorm Cell Therapeutics Inc.
The Income Pick
BCLI has the current edge in this matchup, primarily because of its strength in income & stability.
- beta 1.12
- Better valuation composite
- Beta 1.12 vs AGEN's 2.72
Best for: income & stability
CLLS
Cellectis S.A.
The Growth Play
CLLS ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.
- Rev growth 54.0%, EPS growth 76.8%, 3Y rev CAGR 11.0%
- Lower volatility, beta 1.64, Low D/E 69.8%, current ratio 1.73x
- Beta 1.64, current ratio 1.73x
- 54.0% revenue growth vs FATE's -51.2%
Best for: growth exposure and sleep-well-at-night
FATE
Fate Therapeutics, Inc.
The Healthcare Pick
Among these 5 stocks, FATE doesn't own a clear edge in any measured category.
Best for: healthcare exposure
AGEN
Agenus Inc.
The Quality Compounder
AGEN is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 0.1% margin vs FATE's -20.5%
- 0.1% ROA vs BCLI's -446.1%
Best for: quality and efficiency
NKTR
Nektar Therapeutics
The Long-Run Compounder
NKTR is the clearest fit if your priority is long-term compounding.
- -59.1% 10Y total return vs FATE's 40.5%
- +8.2% vs BCLI's -42.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CLLS | 54.0% revenue growth vs FATE's -51.2% |
| Value | BCLI | Better valuation composite |
| Quality / Margins | AGEN | 0.1% margin vs FATE's -20.5% |
| Stability / Safety | BCLI | Beta 1.12 vs AGEN's 2.72 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | NKTR | +8.2% vs BCLI's -42.7% |
| Efficiency (ROA) | AGEN | 0.1% ROA vs BCLI's -446.1% |
BCLI vs CLLS vs FATE vs AGEN vs NKTR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
FY 2023
FY 2025
FY 2025
BCLI vs CLLS vs FATE vs AGEN vs NKTR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCLLSLAGGINGFATE
Who Leads Where
CLLS leads in 2 of 6 categories
AGEN leads 1 • NKTR leads 1 • BCLI leads 0 • FATE leads 0 • 1 tied
Explore the data ↓FATEFate Therapeutics, In…
0leads
BCLIBrainstorm Cell Thera…
0leads
NKTRNektar Therapeutics
1leads
AGENAgenus Inc.
1leads
CLLSCellectis S.A.
2leads
6 Total Categories
CATEGORYLEADERvs AGENvs NKTRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CLLS3/6
Valuation MetricsMultiples, price ratios, and targets
AGEN2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CLLS4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NKTR4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CLLS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AGEN is the larger business by revenue, generating $114M annually — 134.5x BCLI's $849,000. AGEN is the more profitable business, keeping 0.1% of every revenue dollar as net income compared to FATE's -20.5%. On growth, CLLS holds the edge at +117.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BCLIBrainstorm Cell T… | CLLSCellectis S.A. | FATEFate Therapeutics… | AGENAgenus Inc. | NKTRNektar Therapeuti… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $849,000 | $75M | $7M | $114M | $55M |
| EBITDAEarnings before interest/tax | -$12M | -$6M | -$148M | -$10M | -$130M |
| Net IncomeAfter-tax profit | -$11M | -$35M | -$136M | $115,000 | -$164M |
| Free Cash FlowCash after capex | -$9M | -$33M | -$88M | -$159M | -$209M |
| Gross MarginGross profit ÷ Revenue | +61.5% | +87.6% | — | +35.7% | +99.6% |
| Operating MarginEBIT ÷ Revenue | -14.0% | -35.1% | -22.2% | -17.7% | -2.4% |
| Net MarginNet income ÷ Revenue | -13.5% | -47.0% | -20.5% | +0.1% | -3.0% |
| FCF MarginFCF ÷ Revenue | -11.2% | -43.5% | -13.2% | -139.1% | -3.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +117.1% | -26.4% | +27.5% | -25.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +37.0% | +102.6% | +38.6% | +85.3% | -4.5% |
CLLS leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
AGEN leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BCLIBrainstorm Cell T… | CLLSCellectis S.A. | FATEFate Therapeutics… | AGENAgenus Inc. | NKTRNektar Therapeuti… |
|---|---|---|---|---|---|
| Market CapShares × price | $7M | $280M | $280M | $132M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $8M | $228M | $312M | $140M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | 0.32x | -9.41x | -2.11x | -1102.94x | -8.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 1.79x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.27x | 6.75x | 42.18x | 1.16x | 30.64x |
| Price / BookPrice ÷ Book value/share | — | 2.67x | 1.39x | — | 15.66x |
| Price / FCFMarket cap ÷ FCF | — | 14.35x | — | — | — |
AGEN leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
CLLS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
CLLS delivers a -31.8% return on equity — every $100 of shareholder capital generates $-32 in annual profit, vs $-4 for NKTR. FATE carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to NKTR's 1.66x. On the Piotroski fundamental quality scale (0–9), CLLS scores 7/9 vs NKTR's 2/9, reflecting strong financial health.
| Metric | BCLIBrainstorm Cell T… | CLLSCellectis S.A. | FATEFate Therapeutics… | AGENAgenus Inc. | NKTRNektar Therapeuti… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -31.8% | -65.8% | — | -4.0% |
| ROA (TTM)Return on assets | -4.5% | -9.8% | -42.7% | +0.1% | -62.8% |
| ROICReturn on invested capital | — | -79.6% | -36.5% | — | -57.2% |
| ROCEReturn on capital employed | — | -30.0% | -43.1% | — | -55.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 2 | 6 | 2 |
| Debt / EquityFinancial leverage | — | 0.70x | 0.38x | — | 1.66x |
| Net DebtTotal debt minus cash | $533,000 | -$52M | $31M | $7M | $134M |
| Cash & Equiv.Liquid assets | $187,000 | $143M | $47M | $3M | $15M |
| Total DebtShort + long-term debt | $720,000 | $91M | $78M | $10M | $149M |
| Interest CoverageEBIT ÷ Interest expense | -26.44x | -3.44x | — | 1.11x | -4.74x |
CLLS leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NKTR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NKTR five years ago would be worth $2,765 today (with dividends reinvested), compared to $146 for BCLI. Over the past 12 months, NKTR leads with a +818.2% total return vs BCLI's -42.7%. The 3-year compound annual growth rate (CAGR) favors NKTR at 93.3% vs BCLI's -74.9% — a key indicator of consistent wealth creation.
| Metric | BCLIBrainstorm Cell T… | CLLSCellectis S.A. | FATEFate Therapeutics… | AGENAgenus Inc. | NKTRNektar Therapeuti… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +13.7% | -19.6% | +145.5% | +16.1% | +92.0% |
| 1-Year ReturnPast 12 months | -42.7% | +152.3% | +143.0% | +27.1% | +818.2% |
| 3-Year ReturnCumulative with dividends | -98.4% | +103.2% | -55.4% | -88.2% | +621.8% |
| 5-Year ReturnCumulative with dividends | -98.5% | -76.3% | -96.8% | -93.9% | -72.3% |
| 10-Year ReturnCumulative with dividends | -97.8% | -88.4% | +40.5% | -94.3% | -59.1% |
| CAGR (3Y)Annualised 3-year return | -74.9% | +26.7% | -23.6% | -51.0% | +93.3% |
NKTR leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BCLI and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCLI is the less volatile stock with a 1.12 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 98.6% from its 52-week high vs BCLI's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BCLIBrainstorm Cell T… | CLLSCellectis S.A. | FATEFate Therapeutics… | AGENAgenus Inc. | NKTRNektar Therapeuti… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 1.64x | 2.17x | 2.72x | 1.85x |
| 52-Week HighHighest price in past year | $1.92 | $5.48 | $2.46 | $7.34 | $109.00 |
| 52-Week LowLowest price in past year | $0.46 | $1.33 | $0.91 | $2.71 | $7.99 |
| % of 52W HighCurrent price vs 52-week peak | +36.1% | +70.4% | +98.6% | +51.1% | +76.5% |
| RSI (14)Momentum oscillator 0–100 | 39.3 | 53.2 | 81.0 | 48.8 | 53.4 |
| Avg Volume (50D)Average daily shares traded | 9K | 42K | 1.9M | 814K | 991K |
Evenly matched — BCLI and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CLLS as "Buy", FATE as "Buy", AGEN as "Buy", NKTR as "Buy". Consensus price targets imply 1525.5% upside for FATE (target: $40) vs 55.4% for CLLS (target: $6).
| Metric | BCLIBrainstorm Cell T… | CLLSCellectis S.A. | FATEFate Therapeutics… | AGENAgenus Inc. | NKTRNektar Therapeuti… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $6.00 | $39.50 | $7.33 | $132.83 |
| # AnalystsCovering analysts | — | 17 | 31 | 11 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CLLS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AGEN leads in 1 (Valuation Metrics). 1 tied.
Best OverallCellectis S.A. (CLLS)Leads 2 of 6 categories
Loading custom metrics...
BCLI vs CLLS vs FATE vs AGEN vs NKTR: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is BCLI or CLLS or FATE or AGEN or NKTR a better buy right now?
For growth investors, Cellectis S.
A. (CLLS) is the stronger pick with 54. 0% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Brainstorm Cell Therapeutics Inc. (BCLI) offers the better valuation at 0. 3x trailing P/E, making it the more compelling value choice. Analysts rate Cellectis S. A. (CLLS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BCLI or CLLS or FATE or AGEN or NKTR?
Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -72.
3%, compared to -98. 5% for Brainstorm Cell Therapeutics Inc. (BCLI). Over 10 years, the gap is even starker: FATE returned +40. 5% versus BCLI's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BCLI or CLLS or FATE or AGEN or NKTR?
By beta (market sensitivity over 5 years), Brainstorm Cell Therapeutics Inc.
(BCLI) is the lower-risk stock at 1. 12β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 142% more volatile than BCLI relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.
04Which is growing faster — BCLI or CLLS or FATE or AGEN or NKTR?
By revenue growth (latest reported year), Cellectis S.
A. (CLLS) is pulling ahead at 54. 0% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Brainstorm Cell Therapeutics Inc. grew EPS 148. 9% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, CLLS leads at 11. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BCLI or CLLS or FATE or AGEN or NKTR?
Brainstorm Cell Therapeutics Inc.
(BCLI) is the more profitable company, earning 1369% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 1369% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AGEN leads at -18. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — BCLI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BCLI or CLLS or FATE or AGEN or NKTR more undervalued right now?
Analyst consensus price targets imply the most upside for FATE: 1525.
5% to $39. 50.
07Which pays a better dividend — BCLI or CLLS or FATE or AGEN or NKTR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BCLI or CLLS or FATE or AGEN or NKTR better for a retirement portfolio?
For long-horizon retirement investors, Brainstorm Cell Therapeutics Inc.
(BCLI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 12)). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BCLI: -97. 8%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BCLI and CLLS and FATE and AGEN and NKTR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BCLI is a small-cap deep-value stock; CLLS is a small-cap high-growth stock; FATE is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.